Search

Results from the phase III ARANOTE trial have shown that darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or death by 46% compared to placebo [...]

Bayer will present detailed results from the phase III study OASIS 3, providing supporting efficacy data and sustained safety data over 52 weeks for the investigational compound elinzanetant, adding to [...]

Bayer will present detailed results from the phase III long-term study OASIS 3, evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo, at the upcoming annual [...]

Bayer announced that the first patient has been enrolled in the global phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, assessing the efficacy and safety of investigational agent [...]

Bayer will present late-breaking Phase III data on finerenone (Kerendia) in patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of greater than or equal to 40%, [...]

Bayer announced the start of the ALPINE-1 study, a phase II clinical trial with BAY3283142, an investigational soluble guanylate cyclase (sGC) activator, in patients with chronic kidney disease (CKD). The [...]

Bayer announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the US Food and Drug Administration (FDA) for the treatment of moderate to [...]

Bayer announced initiation of dosing in a phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The investigational candidate, labelled with actinium-225 and comprising a [...]

Bayer will present detailed results from the pivotal phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming [...]

Bayer announced that new long-term results and subgroup analyses from the pivotal clinical trial programme of aflibercept 8 mg (Eylea 8 mg) in neovascular (wet) age-related macular degeneration (nAMD) and [...]

Bayer announced positive topline results of the phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo. In this study, elinzanetant successfully [...]

Bayer announced the start of a phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-a2ap) antibody in patients with deep vein thrombosis (DVT). The results [...]

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized [...]

Vividion Therapeutics, Inc. (Vividion), announced that it has initiated dosing of patients in a phase I clinical trial evaluating VVD-130850, an investigational oral STAT3 inhibitor for the treatment of advanced [...]

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, have announced the initiation of GenePHIT (Gene PHosphatase [...]

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized at the Ohio [...]

Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, presented first-in-human data from a phase 1 trial investigating AB-1002 (also [...]

Bayer expands its phase III OCEANIC clinical development programme for the investigational drug asundexian (BAY2433334) by initiating a third clinical study, OCEANIC-AFINA. OCEANIC AFINA is a phase III study investigating [...]

Vividion Therapeutics, Inc. (Vividion), announced that it has initiated dosing of patients in a phase I oncology clinical trial of its investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, [...]

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced positive top-line results from a phase I clinical [...]

Bayer, a global leader in radiology, has started the phase III clinical development programme QUANTI, aiming to evaluate the efficacy and safety of gadoquatrane, a next-generation, extracellular, macrocyclic, gadolinium-based contrast [...]

Bayer will present new cardiorenal data from the comprehensive Kerendia (finerenone) clinical trial programme in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) at the 60th European [...]

Bayer and its development partner MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA) announced that the first patient has been enrolled in the phase II/III VALOR trial. [...]

Bayer announced the initiation of the phase III QUASAR study, designed to evaluate the efficacy and safety of aflibercept 8 mg dosed at extended treatment intervals compared to the standard [...]

Ionis Pharmaceuticals, Inc. announced positive results from the phase 2b RE-THINC ESRD study of fesomersen (formerly IONIS-FXI-LRx), an investigational antisense medicine designed to reduce the production of Factor XI (FXI) [...]

Bayer will present new renal and cardiovascular (CV) data from the comprehensive Kerendia (finerenone) clinical trial programme in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) at [...]

Bayer, a global leader in women's healthcare, announced that it expands the phase III clinical development programme OASIS by initiating OASIS 4 -- a phase III study in breast cancer [...]

Bayer announced the start of a phase III clinical development programme 'OCEANIC' to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor, as a potential new [...]

Bayer will present new renal and cardiovascular data from the comprehensive Kerendia (finerenone) clinical trial programme at the 2022 American Diabetes Association (ADA) 82nd Scientific Sessions. This new data will [...]

BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?the completion of enrollment of its phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons [...]

Bayer will present a range of new clinical data at the American College of Cardiology's 71st Annual Scientific Session (ACC.22), 2-4 April, including data on the non-steroidal, selective mineralocorticoid receptor [...]

Bayer announced the initiation of the CONFIDENCE study, a phase II, three-arm study that will investigate simultaneous initial combination therapy with finerenone and the SGLT2 inhibitor empagliflozin, compared with finerenone [...]

Results from the phase III ARASENS trial have shown that the use of the oral androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly increased overall [...]

Bayer announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients [...]

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced the closeout of the first of two cohorts in its ongoing phase 1 (Ph1), open-label trial [...]

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia) clinical trial programme, including the phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis [...]

Bayer announced the initiation of the FIND-CKD study, a multicenter, randomized, double-blind, placebo-controlled phase III study for an investigational new use of Kerendia (finerenone) in addition to guideline-directed therapy, on [...]

Bayer announced the results from PAGANINI, the phase IIb dose-finding study evaluating the efficacy and safety of its investigational orally administered, potent and selective P2X3 receptor antagonist eliapixant (BAY1817080) in [...]

Bayer, a global leader in women's healthcare, announced that it started the phase III clinical development programme OASIS, which aims to evaluate the efficacy and safety of the investigational compound, [...]

Bayer announced the initiation of the FINEARTS-HF study, a multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of finerenone on morbidity and mortality in patients [...]

Bayer and Pharmaron, a premier R&D service company, have entered into a global collaboration agreement to develop new molecular entities for veterinary medicines. Under the collaboration, Bayer will fully leverage [...]

Bayer has initiated a phase III trial of its anti- VEGF treatment aflibercept for intravitreal injection in retinopathy of prematurity (ROP), an eye condition in premature infants which can lead [...]

The phase III ARAMIS (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) met its primary endpoint. Darolutamide significantly extended [...]

Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments based on patient or tumor characteristics [...]